Showing Publications: 1–9 of 9
-
Sep
1
2011
Lasmiditan (COL-144) a Selective 5-HT1F agonist, is a rapid & effective oral treatment for acute migraine
Source: European Headache & Migraine Trust Ingernational Congress 2010
- Sep 1 2011
-
Jun
15
2010
Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial
Lasmiditan (COL-144; LY573144) is a novel, highly selective and potent agonist at 5-HT1F receptors that lacks vasoconstrictor activity. Preclinical and early clinical experiments predict acute ntimigraine efficacy of COL-144 that is mediated through a non-vascular, primarily neural, mechanism.
Source: Cephalalgia
- Jun 15 2010
-
Sep
11
2009
Prediction of Therapeutically Effective Dose of COL-144 Based on Relationship Between Plasma Concentrations and Headache Response
Source: 14th International Headache Congress; Philadelphia, PA
-
Sep
11
2009
COL-144 an Orally Bioavailable Selective 5-HT1F Receptor Agonist for Acute Migraine Therapy
Source: European Headache & Migraine Trust International Congress 2008; London, England, Poster #PC.11
-
Sep
5
2008
COL-144: Preclinical Profile of a Selective 5-HT1F Receptor Agonist for Migraine
Source: European Headache & Migraine Trust International Congress 2008; London, England, Poster #PC.12
-
Sep
5
2008
COL-144: A Selective 5-HT1F Agonist For the Treatment of Migraine Attacks
Source: European Headache & Migraine Trust International Congress 2008
-
Sep
1
2005
Can We Develop Neurally Acting Drugs for the Treatment of Migraine?
Serotonin (5-HT)1B/1D receptor agonists, which are also known as triptans, represent the most important advance in migraine therapeutics in the four millennia that the condition has been recognized. The vasoconstrictive activity of triptans produced a small clinical penalty in terms of coronary vasoconstriction but also raised an enormous intellectual question: to what extent is migraine a vascular problem? Functional neuroimaging and neurophysiological studies have consistently developed the theme of migraine as a brain disorder and, therefore, demanded that the search for neurally acting antimigraine drugs should be undertaken. The prospect of non-vasoconstrictor acute migraine therapies, potential targets for which are discussed here, offers a real opportunity to patients and provides a therapeutic rationale that places migraine firmly in the brain as a neurological problem, where it undoubtedly belongs.
Source: Nature Publishing Group, Vol 4